M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 3.55 USD 2.9% Market Closed
Market Cap: 374.5m USD
Have any thoughts about
MaxCyte Inc?
Write Note

MaxCyte Inc
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

MaxCyte Inc
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
M
MaxCyte Inc
NASDAQ:MXCT
Stock-Based Compensation
$14m
CAGR 3-Years
78%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Stock-Based Compensation
$283m
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
10%
Danaher Corp
NYSE:DHR
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Stock-Based Compensation
$19.1m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

MaxCyte Inc
Glance View

Market Cap
373.8m USD
Industry
Life Sciences Tools & Services

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

MXCT Intrinsic Value
3.35 USD
Overvaluation 6%
Intrinsic Value
Price
M

See Also

What is MaxCyte Inc's Stock-Based Compensation?
Stock-Based Compensation
14m USD

Based on the financial report for Dec 31, 2023, MaxCyte Inc's Stock-Based Compensation amounts to 14m USD.

What is MaxCyte Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
60%

Over the last year, the Stock-Based Compensation growth was 19%. The average annual Stock-Based Compensation growth rates for MaxCyte Inc have been 78% over the past three years , 60% over the past five years .

Back to Top